| 1975-05 |
DOMS-IATRON Co., Ltd. (currently Kainos) was established with a capital stock of 30,000,000 yen as a developer of new products in the health care industry. |
| 1975-05-01 |
Established: May 1, 1975. |
| 1975-07 |
Changed its name to Kainos Laboratories, Inc. |
| 1975-07 |
Name changed to Kainos Laboratories, Inc. |
| 1975-09 |
Released the world’s first enzyme-based serum transaminase measurement reagent kit. |
| 1975-09 |
Released the world's first enzyme-based serum aspartate transaminase measurement kit. |
| 1976-12 |
Formed a technical tie-up with Mitsui Pharmaceutical Industry Co. (Currently Bayer Yakuhin,Ltd.) on enzyme immunoassay method (EIA). |
| 1976-12 |
Entered into a technology partnership with Mitsui Pharmaceutical (now Bayer Pharmaceuticals) regarding enzyme immunoassay (EIA). |
| 1981-04 |
Entered into a technical tie-up agreement with Hitachi Chemical Co., Ltd.(Currently Hitachi Chemical Diagnostics Systems Co., Ltd.) on reagents for clinical analysis equipment. |
| 1981-04 |
Entered into a technology partnership with Hitachi Chemical (now Hitachi Chemical Diagnostics Systems) regarding clinical analytical reagents. |
| 1983-03 |
Entered into a sales agreement for blood transfusion diagnostics products with GAMMA BIOLOGICALS, Inc (USA) |
| 1983-03 |
Signed a sales agreement with the U.S. company GAMMA BIOLOGICALS for blood transfusion diagnostic products. |
| 1983-03 |
Entered into a sales agreement for blood transfusion diagnostics products with GAMMA BIOLOGICALS, Inc (USA). |
| 1983-04 |
Released an enzyme-based creatinine measurement reagent kit. |
| 1983-04 |
Released an enzyme-based creatinine measurement reagent. |
| 1987-06 |
Entered into a technical tie-up agreement with Nippon Kayaku Co., Ltd. on clinical examination reagents. |
| 1987-06 |
Entered into a technology partnership with Nihon Kakyaku regarding clinical test reagents. |
| 1992-09 |
Entered into a technical tie-up agreement with Kirin Beer Co., Ltd. (Currently Kyowa Kirin Co., Ltd.) on clinical examination reagents. |
| 1992-09 |
Entered into a technology partnership with Kirin Brewery (now Kirin Company) regarding clinical test reagents. |
| 1993-03 |
Moved production to Kasama Factory, and began production of biochemical and immunoserological reagents. |
| 1993-03 |
Moved production to the Kasama factory and began manufacturing biochemical and immunohematology reagents. |
| 1993-10 |
Entered into a technical tie-up agreement with Asahi Chemical Industry Co., Ltd. (Currently Asahi Kasei Pharma Corporation) on clinical examination reagents. |
| 1993-10 |
Entered into a technology partnership with Asahi Chemical Industry (now Asahi Kasei Pharma) regarding clinical test reagents. |
| 1995-10 |
Moved the Head Office to Hongo, Bunkyo-ku, Tokyo. |
| 1995-10 |
Relocated headquarters to Hongo, Tokyo. |
| 1995-12 |
Listed on JASDAQ. |
| 1995-12 |
Listed on JASDAQ. |
| 2000-06 |
Acquired ISO 9001 certification, an international standard for quality assurance. |
| 2000-06 |
Obtained ISO 9001 certification. |
| 2000-10 |
Entered into the licence agreement of NASBA Patents with Organon Teknika B. V.(Ownership of the “NASBA Gene Amplification” patent has been transferred from Organon Teknika B.V. to bioMerieux.) |
| 2000-10 |
Signed a licensing agreement for NASBA patents with Organon Teknika B.V. (ownership transferred to bioMerieux). |
| 2004-05 |
Entered into a distributorship agreement for genetic products with bioMerieux Japan. |
| 2004-05 |
Entered into a distribution agreement for gene-related products with bioMerieux Japan. |
| 2004-11 |
Launched marketing of an influenza detection reagent “Statmark™ Influenza A/B” that had been jointly developed by Nichirei Corporation (currently Nichirei Bioscience Inc,) and Kainos. |
| 2004-11 |
Commenced sales of the Statmark™ Influenza A/B detection kit jointly developed with Nichirei. |
| 2005-07 |
Created Kainos BB, Co. Ltd. by spinning out Kainos’ Blood Banking business (in June 2005) then changed the name of the spun out company to Immucor-Kainos, Inc. through a joint venture agreement established as a part of the ongoing collaborative effort between Immucor, Inc. and Kainos. |
| 2005-07 |
Divested the blood bank business and established Kainos BB, Co. Ltd., later renamed Immucor-Kainos, Inc. |
| 2006-05 |
Acquired ISO 13485 certification, an international standard for quality assurance of in vitro medical equipment. |
| 2006-05 |
Obtained ISO 13485 certification. |
| 2007-10 |
Acquired ISO 13485 certification, an international standard for quality assurance of in vitro medical equipment. |
| 2007-10 |
Reobtained ISO 13485 certification. |
| 2008-04 |
Introduction of the Kainos Executive Office System. Established Compliance Center. |
| 2008-04 |
Implemented the Kainos Executive Office System and established a Compliance Center. |
| 2008-05 |
Kainos-Immucor, Inc.’s (currently K. K. Immucor) stocks were transferred to Immucor, Inc. |
| 2008-05 |
Shares of Kainos-Immucor, Inc. were transferred to Immucor, Inc. |
| 2011-09 |
Entered into a distributorship agreement for blood transfusion diagnostics products with Grifols SA. |
| 2011-09 |
Entered into a distribution agreement for blood transfusion diagnostic products with Grifols SA. |
| 2018-02 |
Insurance coverage granted to the assays respectively measuring two fractions of blood carnitine using blood carmitine measuring reagents based on the enzyme cycling method. |
| 2018-02 |
Obtained insurance coverage for a reagent measuring two fractions of plasma carnitine using an enzymatic cycle method. |
| 2018-04 |
Insurance coverage granted to the diagnostic drug based on an ADAMTS13 activity measurement reagent for the thrombotic thrombocytopenic purpura. |
| 2018-04 |
Obtained insurance coverage for a diagnostic reagent measuring ADAMTS13 activity. |
| 2019-05 |
Signed a share transfer agreement with Asahi Kasei Pharma, strengthening mutual business relations. |
| 2019-05 |
Concluded a share transfer agreement with Asahi Kasei Pharma Corporation to further enhance the mutual business relationship. |
| 2020-09 |
Capital tie-up with Gene Therapy Research Institution Co.,Ltd. by accepting a part of its third-party allotment of shares. |
| 2020-09 |
Implemented a capital partnership with Gene Therapy Research Institution and accepted a third-party allotment of shares. |
| 2022-02 |
Concluded a capital and business tie-up with Sysmex Corporation to further enhance the mutual business relationship. |
| 2022-02 |
Entered into a capital and business partnership with Sysmex Corporation. |
| 2026-06 |
Delisted from the Tokyo Stock Exchange Standard Market. Became a wholly owned subsidiary of Denka Co., Ltd. |
